Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20258282 | 1.00 | STS (0.35) | STSUSP30SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL17956400 | 0.92 | USP30 (0.37) | STSUSP30KMT2AL3MBTL1YAP1 | |
| SCHEMBL18044440 | 0.92 | USP30 (0.37) | STSUSP30KMT2AL3MBTL1YAP1 | |
| SCHEMBL20258276 | 0.92 | USP30 (0.37) | STSUSP30KMT2AL3MBTL1YAP1 | |
| SCHEMBL21847863 | 0.89 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL17956503 | 0.88 | USP30 (0.36) | STSUSP30KMT2AL3MBTL1YAP1 | |
| SCHEMBL20258290 | 0.88 | USP30 (0.36) | STSUSP30KMT2AL3MBTL1YAP1 | |
| SCHEMBL20258292 | 0.87 | SMN1; SMN2 (0.37) | STSUSP30SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL20258281 | 0.80 | JAK2 (0.36) | STSUSP30SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL19409528 | 0.80 | JAK2 (0.36) | STSUSP30SMN1; SMN2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348578-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| US-11414417-B2 | Crystalline forms of diazabicyclooctane derivative and production process thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3299370-B1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-11-24 | — | — | EP | disclosed |
| EP-3067355-B1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20200181143-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| CN-111153903-A | Crystal of diazabicyclooctane derivative, preparation method and application thereof, and pharmaceutical composition | 明治制果药业株式会社 | 2020-05-15 | — | — | CN | disclosed |
| EP-3050883-B1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVES AND INTERMEDIATES | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-10604522-B2 | Processes for producing diazabicyclooctane compounds | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| EP-3613741-A1 | PREPARATION OF A DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613740-A1 | PREPARATION OF A DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20190031659-A1 | PROCESSES FOR PRODUCING DIAZABICYCLOOCTANE COMPOUNDS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-10131665-B2 | Processes for producing diazabicyclooctane compounds | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-11-20 | — | — | US | disclosed |
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20160272641-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067355-A1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3050883-A1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348578-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | CCNA1, RCC1, DDT | STS 3504/4885USP30 3968/4885SMN1; SMN2 4346/4885 |
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | OGFOD1, HAAO, CLCN2 | STS 3633/4885USP30 2537/4885SMN1; SMN2 4762/4885 |
| US-20160272641-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | DDT, CYP51A1, ODC1 | STS 888/4885USP30 4231/4885SMN1; SMN2 4590/4885 |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | OGFOD1, HAAO, CLCN2 | STS 3633/4885USP30 2537/4885SMN1; SMN2 4762/4885 |
| US-10604522-B2 | Processes for producing diazabicyclooctane compounds | DHCR7, C9, CYCS | STS 482/4885USP30 3686/4885SMN1; SMN2 2133/4885 |
| US-20190031659-A1 | PROCESSES FOR PRODUCING DIAZABICYCLOOCTANE COMPOUNDS | DHCR7, C9, CYCS | STS 482/4885USP30 3686/4885SMN1; SMN2 2133/4885 |
| US-11414417-B2 | Crystalline forms of diazabicyclooctane derivative and production process thereof | CCNA1, RCC1, DDT | STS 3504/4885USP30 3968/4885SMN1; SMN2 4346/4885 |
| US-20200181143-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | CCNA1, RCC1, DDT | STS 3504/4885USP30 3968/4885SMN1; SMN2 4346/4885 |
| US-10131665-B2 | Processes for producing diazabicyclooctane compounds | DDT, ODC1, CYP51A1 | STS 459/4885USP30 4131/4885SMN1; SMN2 3936/4885 |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | CLCN2, ODC1, KCNN4 | STS 3538/4885USP30 3438/4885SMN1; SMN2 4784/4885 |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | CLCN2, ODC1, KCNN4 | STS 3538/4885USP30 3438/4885SMN1; SMN2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.